Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI).

MLA

Peters, Esther, et al. “Study Protocol for a Multicentre Randomised Controlled Trial: Safety, Tolerability, Efficacy and Quality of Life Of a Human Recombinant Alkaline Phosphatase in Patients with Sepsis-Associated Acute Kidney Injury (STOP-AKI).” BMJ Open, vol. 6, no. 9, Sept. 2016, p. e012371. EBSCOhost, https://doi.org/10.1136/bmjopen-2016-012371.

APA

Peters, E., Mehta, R. L., Murray, P. T., Hummel, J., Joannidis, M., Kellum, J. A., Arend, J., & Pickkers, P. (2016). Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI). BMJ Open, 6(9), e012371. https://doi.org/10.1136/bmjopen-2016-012371

Chicago

Peters, Esther, Ravindra L Mehta, Patrick T Murray, Jürgen Hummel, Michael Joannidis, John A Kellum, Jacques Arend, and Peter Pickkers. 2016. “Study Protocol for a Multicentre Randomised Controlled Trial: Safety, Tolerability, Efficacy and Quality of Life Of a Human Recombinant Alkaline Phosphatase in Patients with Sepsis-Associated Acute Kidney Injury (STOP-AKI).” BMJ Open 6 (9): e012371. doi:10.1136/bmjopen-2016-012371.